DBV Technologies

174 articles with DBV Technologies

• DBV Technologies Announces Clinical Trial Agreement To Develop A Treatment For Milk-Induced Eosinophilic Esophagitis In Children

  5/13/2014

• DBV Technologies To Host And Webcast Investor Day In New York City On May 21, 2014

  5/12/2014

• DBV Technologies Announces The First Reported Case Of A Long Term Sustained Effect Of Peanut Desensitization After Epicutaneous Immunotherapy (EPIT) With Viaskin® At The French Congress Of Allergy

  4/16/2014

• DBV Technologies Announces Topline Financial Results For First Three Months 2014

  4/15/2014

• DBV Technologies And CEA Conclude A Scientific Cooperation To Investigate Epigenetic Modulation In Epicutaneous Immunotherapy

  4/9/2014

• DBV Technologies Announces Creation Of US Subsidiary And Appoints Ms. Susanna Mesa As Vice President Of Finance, U.S. Investor Relations & Strategy

  4/7/2014

• DBV Technologies Release: Additional Contribution To The Liquidity Agreement With Natixis

  4/1/2014

• DBV Technologies Announces Data Presentations For EPIT At The European Academy Of Allergy And Clinical Immunology (EAACI) Congress 2014

  3/25/2014

• DBV Technologies Technologies Reports Full Year 2013 Financial Results And Provides VIPES Update

  3/17/2014

• DBV Technologies Release: Presentation And Publication Of Research At American Academy of Allergy, Asthma and Immunology (AAAAI) Demonstrates EPIT(TM)'S Ability To Rebalance The Immune System And Induce A Disease-Modifying Effect

  3/5/2014

• DBV Technologies To Present At The Barclays Global Healthcare Conference In Miami, USA

  3/4/2014

• DBV Technologies And Mount Sinai Hospital Enter Research Collaboration For Crohn's Disease

  2/18/2014

• DBV Technologies Reports Full Year 2013 Topline Financial Results

  1/30/2014

• DBV Technologies To Present Key Scientific Publications At The American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Conference

  1/29/2014

• DBV Technologies Provides 2013 Year-End Summary And News Flow Guidance For 2014

  12/17/2013

• DBV Technologies Enters Into Collaboration Agreement With Bionet-Asia And University of Geneva On Whooping Cough Booster Vaccine

  11/26/2013

• National Institutes of Health (NIH)-Sponsored Consortium of Food Allergy Research (CoFAR) Starts a Phase 2 Clinical Study With DBV Technologies' Viaskin® Peanut in the Treatment of Peanut Allergy

  10/24/2013

• DBV Technologies Forms Research Collaboration With INSERM to Develop Viaskin® for Refractory Hemophilia A Disease

  10/23/2013

• Stallergenes, S.A. Inks $198 Million Pact for Allergy R&D With DBV Technologies

  10/18/2013

• DBV Technologies Announces Topline Financial Results for First Nine Months 2013 and Provides Safety Update on Viaskin® Peanut

  10/15/2013